Industry / United Kingdom

Eisai Open European Knowledge Centre

June 2009 | Industry Trend Analysis

Despite the local pricing regulator recently turning down the expanded use of its key drug, Japanese pharmaceutical company

To read the full article, please sign in or take a free trial.

Related Insight Articles

Takeda Emerging Markets Sales Drop

Industry / Japan BMI View: Takeda will continue to underperform its rivals over the medium term. Sales, net income and earnings per share (EPS) all declined in the most recent financial reporting period. The company has...

August 2010

Leading Drugmaker Highlights Concerning Situation

Industry / United Kingdom GlaxoSmithKline Pakistan's financial performance has been impaired by a challenging business environment, according to the company's senior executive. In an interview with Bloomberg, Chairman and CEO M....

July 2010

GSK To Increase Its Investment In Asia

Industry / United Kingdom Multinational drugmaker GlaxoSmithKline (GSK) is looking to invest in small- and medium-sized pharmaceutical and biotechnology companies in Japan, reinforcing the company's strategic priority - to grow...

March 2010

Wockhardt To Distribute Sinclair Pharma's Medicines

Industry / United Kingdom In an effort to penetrate emerging markets, UK specialty drugmaker Sinclair Pharma has contracted Mumbai-based Wockhardt to distribute four of its products in India. The deal runs for 10 years and has...

June 2008

Health Ministry Sidelines Industry On Price Cuts?

Companies / Japan Pharmaceutical industry sources have questioned the intentions of Japan's health ministry (MHLW), following claims that officials are to introduce annual drug price cuts despite ongoing consultations...

July 2006